Browsing Tag

DFD29

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical…

Eli Pacheco Jun 14, 2023 0

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16…

Health

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data…

Eli Pacheco Dec 21, 2022 0

SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the…

Health

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial…

Eli Pacheco Mar 17, 2022 0

SCOTTSDALE, Ariz., March 17, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the…